In summary, BIM deletion polymorphism might be a genetic cause of intrinsic resistance to TKI therapy in EGFR-mutated NSCLC and it could be emerged as an independent predictive biomarker to identify patients who would benefit from TKI targeted therapy in EGFR-mutated NSCLC. The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.